<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_Slovenia_Background_The_problem"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu"><UL><LI class="selected"><A href="/Team:Slovenia/Background/The_problem">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:Slovenia/Background/The_problem&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:Slovenia/Background/The_problem&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:Slovenia/Background/The_problem&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:Slovenia/Background/The_problem" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:Slovenia/Background/The problem</H1><DIV id="bodyContent"><H3 id="siteSub">From 2008.igem.org</H3><DIV align="center" style="width:900px; background-color:#528e68; text-align:center;"><UL id="sddm"><LI><DIV id="m1" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="#" target="_self">The problem</A><A href="https://2008.igem.org/Team:Slovenia/Background/Modern_vaccines" target="_self">Modern vaccines</A><A href="https://2008.igem.org/Team:Slovenia/Background/Immune_response" target="_self">Immune response</A><A href="https://2008.igem.org/Team:Slovenia/Background/Flagellin" target="_self">Flagellin</A></DIV></LI><LI><DIV id="m2" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2008.igem.org/Team:Slovenia/Project/Motivation" target="_self">Motivation</A><A href="https://2008.igem.org/Team:Slovenia/Project/Engineered_flagellin_vaccine" target="_self">Engineered flagellin vaccine</A><A href="https://2008.igem.org/Team:Slovenia/Project/Antigen-TLR_fusion_vaccine" target="_self">Antigen-TLR fusion vaccine</A></DIV></LI><LI><DIV id="m3" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2008.igem.org/Team:Slovenia/Results/Engineered_flagellin_vaccine" target="_self">Engineered flagellin vaccine</A><A href="https://2008.igem.org/Team:Slovenia/Results/Antigen-TLR_fusion_vaccine" target="_self">Antigen-TLR fusion vaccine</A><A href="https://2008.igem.org/Team:Slovenia/Results/Real-life_results" target="_self">&quot;Real-life&quot; results</A><A href="https://2008.igem.org/Team:Slovenia/Results/Biobricks" target="_self">Biobricks</A></DIV></LI><LI><DIV id="m4" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2008.igem.org/Team:Slovenia/Notebook/Methods" target="_self">Methods</A><A href="https://2008.igem.org/Team:Slovenia/Notebook/Safety" target="_self">Safety</A><A href="https://2008.igem.org/Team:Slovenia/Notebook/References" target="_self">References</A><A href="https://2008.igem.org/Team:Slovenia/Notebook/Notebook" target="_self">Notebook</A></DIV></LI><LI><DIV id="m5" onmouseover="mcancelclosetime()" onmouseout="mclosetime()"><A href="https://2008.igem.org/Team:Slovenia/Acknowledgements" target="_self">Acknowledgements</A><A href="https://2008.igem.org/Team:Slovenia/Sponsors" target="_self">Sponsors</A></DIV></LI></UL></DIV><P><CENTER><FONT size="6" color="#C73E4A"><I>The problem - infection with <I>Helicobacter pylori</I></I></FONT></CENTER></P><DIV style="text-align:justify"><I>Helicobacter pylori</I> are helix-shaped, microaerophilic bacteria with polar flagella that live near the surface of the human gastric mucosa. Approximately half of the world`s population harbors <I>H. pylori</I> in their upper gastrointestinal tract, with 3rd world countries being most affected. There is evidence of co-evolution of human and <I>H. pylori</I>, tracing the migration of human race in the last tens of thousands of years (Covacci et al., 1999).</DIV></DIV><DIV align="center"><P><I>Helicobacter pylori</I></P></DIV><DIV align="center"><P> Global prevalence of <I>H. pylori</I> infection</P></DIV><DIV style="text-align:justify">
Infection with <I>H. pylori</I> is usually acquired early in childhood and lasts for a lifetime, and the majority of those infected (80%–90%) remain asymptomatic. However, infection with <I>H. pylori</I> is known to be the strongest risk factor for the development of peptic ulcers. Furthermore, <I>H. pylori</I> was the first bacterium to be classified as a definite carcinogen by the WHO. Thus, from the medical point of view, <I>H. pylori</I> represents a challenging pathogen responsible for much mortality worldwide.

The generally accepted route of transmission for <I>H. pylori</I> is from person to person, e.g. by oral-oral transmission, since <I>H. pylori</I> can only survive for short periods of time because it is rapidly killed by higher oxygen tension and light. Therefore, infection with <I>H. pylori</I> is considered as a &quot;kissing disease&quot;.

Infection with <I>H. pylori</I> can lead to several clinical outcomes. By far the most common gastric phenotype is the »simple gastritis« which is characterized by mild inflammation of the stomach lining and little disruption of gastric acid secretion. The second main phenotype is the duodenal ulcer phenotype (duodenum is the beginning portion of the small intestine) which accounts for up to 15 % in infected subjects. Subjects with this phenotype have defective inhibitory control of gastric acid secretion, which leads to very high acid output and consequently the development of peptic ulcers.</DIV><CENTER>

If untreated, peptic ulcers can commonly result in haemorrhage into the 
stomach or the abdominal cavity which often leads to severe blood loss 
and even death.<FONT size="1">Image from http://medicalimages.allrefer.com/large/ulcer-emergencies. jpg</FONT></CENTER><DIV style="text-align:justify">
The third and most serious phenotype is the »gastric cancer phenotype«, which is, in contrast to the previous two phenotypes, characterized with hypo- or achlorhydria (low acid secretion) and affects up to 5% of infected subjects. Gastric cancer is a formidable disorder, primarily because most patients are diagnosed at an advanced stage of disease. Despite the curative surgical resection vast majority of affected individuals often die of recurrent disease.  
  
Interestingly, <I>H. pylori</I> is the only known organism capable of colonizing the severe environment of the human stomach, but even this bacterium can withstand low pH for only short periods of time. <I>H. pylori</I> has developed several mechanisms to avoid bactericidal activity of HCl. It uses its polar flagella for motility in chemotactic response to pH gradient, by which it stays in close proximity to the surface of the epithelium, where pH is near neutral. Besides that, <I>H. pylori</I> was shown to be capable of adhering to the surface and even invading the epithelial cells so as to protect itself from gastric contents and mechanical clearance to promote perseverance. <I>H. pylori</I> also possesses artificial means of increasing pH in its direct proximity by generating large quantities of cytosolic and cell surface-associated urease, an enzyme capable of the breakdown of urea into ammonia and carbon dioxide.
  
Alongside the capability of breaching the cellular and physical barriers, <I>H. pylori</I> has additionally developed ways of avoiding both the innate and the adaptive immune response of the host organism. To date, several bacterial strategies have been described (some of them are illustrated in table and figure below). For example, <I>H. pylori</I> flagellar proteins have developed in a way that masks them from the Toll-like receptor 5 (an innate immune receptor, that recognizes various other bacterial flagellins). LPS from <I>H. pylori</I> is 1000 times less pyrogenic and 500-fold less toxic than that of gram-negative enteric bacteria due to modifications that mimic human glycans and therefore induces less inflammation. <I>H. pylori</I> is also capable of obtaining cholesterol directly from epithelial cell membranes and incorporating it into its own lipid layer. To escape macrophage phagocytosis it modifies obtained cholesterol by adding a glucosyl group (a reaction catalysed by cholesterol-α glucosyltransferase). Additionally, <I>H. pylori</I> reduces generation of bactericidal nitric oxide by the macrophage. Its enzyme arginase competes with macrophages inducible nitric oxide synthase for substrate L-arginine that is used by the bacteria for the synthesis of urea (a substrate for urease). Moreover, exposure to <I>H. pylori</I> products upregulates transcription of arginase II in macrophages, which catalyses breakdown of L-arginine into urea and L-ornithine that is subsequently metabolized into polyamines that trigger apoptosis in macrophages.
</DIV><LEFT><LEFT><FONT size="2"><SPAN style="font-size: 100%; text-align:justify"><I>Helicobacter pylori</I> modifies its LPS and flagellin so that they do not activate Toll-like receptors 4 and 5 
opposite to LPS and flagellin of <I>Escherichia coli</I>),  which results in no activation of the immune system cells.
 
Summary of strategies that <I>H. pylori</I> employs to avoid detection of the immune system
</SPAN></FONT><P><TABLE border="1" cellpadding="0" cellspacing="0"><TBODY><TR><TD style="border: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168"><STRONG><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">MECHANISM</FONT></SPAN></SPAN></STRONG></TD><TD style="border-color: black black black rgb(236, 233, 216); border-top: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><STRONG><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">EXAMPLE</FONT></SPAN></SPAN></STRONG></TD></TR><TR><TD style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">Bypassing the TLR system</FONT></SPAN></SPAN></TD><TD style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- Flag</FONT></SPAN></SPAN><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">ellin fails to activate TLR5 </FONT><FONT color="#000000">(Gewirtz et al., 2004)</FONT></SPAN></SPAN><SPAN style="background-color: rgb(255, 255, 255);"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">-</FONT><SPAN style="color: black;">Tetraacylated LPS poorly activates TLR4 and may actually work as an antagonist</SPAN><SPAN style="color: black;">(Moran and Aspinall, 1998)</SPAN></SPAN></SPAN></SPAN><SPAN style="background-color: rgb(255, 255, 255);"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt; color: black;">- DNA is rich in A/T nucleotides and frequently methylated, making TLR9 response more unprobable (Blaser and Atherton, 2004)</SPAN></SPAN></SPAN></TD></TR><TR><TD style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">Minimization of innate immunity</FONT></SPAN></SPAN></TD><TD style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- Modification of LPS (<SPAN style="color: black;">long 3-hydroxy fatty acids of lipid A, unusual phosphorylation pattern…)</SPAN><SPAN style="background-color: rgb(255, 255, 255);"><SPAN style="color: black;">(Moran et al., 1997, 1998)</SPAN></SPAN></FONT></SPAN></SPAN></TD></TR><TR><TD style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">Mimicry of host antigens</FONT></SPAN></SPAN></TD><TD style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- Lewis expression (</FONT><SPAN style="color: black;">O antigen region of <I>H. pylori</I> LPS)</SPAN><SPAN style="background-color: rgb(255, 255, 255);"><SPAN style="color: black;">(Wirth et al., 1997)</SPAN></SPAN></SPAN></SPAN></TD></TR><TR><TD style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">Antigenic variation</FONT></SPAN></SPAN></TD><TD style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">Cag</FONT><SPAN style="background-color: rgb(255, 255, 255);"><FONT color="#000000">Y (Aras et al., 2003)</FONT></SPAN></SPAN></SPAN></TD></TR><TR><TD style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">Host gene expression modulation</FONT></SPAN></SPAN></TD><TD style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt; color: black;">- Upregulation of specific inflammatory and immune mediators including β-defensin, protease inhibitor, chemokine rec</SPAN><SPAN style="background-color: rgb(255, 255, 255);"><SPAN style="font-size: 10pt; color: black;">eptor, interleukin-1β, tumor necrosis factor-α-inducible protein… (Israel and Peek, 2006)</SPAN></SPAN></SPAN></TD></TR><TR><TD style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">Downregulation of immune effectors</FONT></SPAN></SPAN></TD><TD style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt; color: black;">- Blocking the proliferation of T cell through VacA</SPAN><SPAN style="font-size: 10pt;"><SPAN><FONT color="#000000"> </FONT></SPAN><SPAN style="color: black;">and<SPAN> </SPAN>B cell proliferation<SPAN> </SPAN> through Cag</SPAN></SPAN></SPAN><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><SPAN style="color: black;">A-induced supression</SPAN></SPAN></SPAN><SPAN style="background-color: rgb(255, 255, 255);"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt; color: black;">- Interference with phagocytosis</SPAN><SPAN style="font-size: 10pt; color: black;">(Baldari et al., 2005)</SPAN></SPAN></SPAN></TD></TR><TR><TD style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">Avoidance of attack by ROIs and RNIs</FONT></SPAN></SPAN></TD><TD style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- Enzymes involved in ROI scavenging, such as catalase and superoxide dismutase</FONT></SPAN></SPAN><SPAN style="background-color: rgb(255, 255, 255);"> </SPAN><SPAN style="background-color: rgb(255, 255, 255);"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- Arginase regulates NO synthesis <SPAN style="color: black;">(Baldari et al., 2005)</SPAN></FONT></SPAN></SPAN></SPAN></TD></TR><TR><TD style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; background-color: transparent;" valign="top" width="168"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">Ability to colonize gastric environment</FONT></SPAN></SPAN></TD><TD style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; background-color: transparent;" valign="top" width="339"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- Neutralizing pH around the organism with urease enzyme</FONT></SPAN></SPAN><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- Interaction between adhesins and<SPAN> </SPAN>local cell receptors</FONT></SPAN></SPAN><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- Expressing mucolytic molecules</FONT></SPAN></SPAN><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- Relative absence of immune cells in gastric mucosa and rare competition with commensal bacteria</FONT></SPAN></SPAN></TD></TR><TR style="height: 46.55pt;"><TD style="border-color: rgb(236, 233, 216) black black; border-left: 1pt solid black; border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 125.9pt; height: 46.55pt; background-color: transparent;" valign="top" width="168"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">High mutational and recombinational frequency, high diversity</FONT></SPAN></SPAN></TD><TD style="border-color: rgb(236, 233, 216) black black rgb(236, 233, 216); border-right: 1pt solid black; border-bottom: 1pt solid black; padding: 0cm 5.4pt; width: 254.25pt; height: 46.55pt; background-color: transparent;" valign="top" width="339"><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- Rapid development in the bacterial population of high-level resistance to commonly used antibiotics</FONT></SPAN></SPAN><SPAN style="font-family: Arial;"><SPAN style="font-size: 10pt;"><FONT color="#000000">- High competence for uptake of DNA from other <I>H. pylori</I> strains</FONT><SPAN style="background-color: rgb(255, 255, 255);"><FONT color="#000000">(Sansonetti and Di Santo, 2007)</FONT></SPAN></SPAN></SPAN></TD></TR></TBODY></TABLE></P><DIV style="text-align:justify">
There is also experimental evidence linking bacterial adhesion and disease progression as an outcome of delivery of toxins, for instance VacA (pore-forming cytotoxin) that is characterized as a potent inhibitor of T-cell function and believed to be capable of inserting into the membranes of late endosomal vesicles to perturb antigen presentation. VacA can also disrupt the barrier function of tight junctions and thereby causes leakage of ions and small molecules from host cells, so that <I>H. pylori</I> can acquire nutrients across an intact epithelial barrier. 

Current medical treatment of peptic ulcers and <I>H. pylori</I> infection consists mainly of three- and four-drug regimes, which combine two antibiotics with either proton pump inhibitors to reduce the production of gastric acid and/or cytoprotective agents that protect cells from toxic chemicals or other stimuli. Although these regimes are very effective at eradicating <I>H. pylori</I> with cure rates higher than 90%, there remains a serious problem of increasing antibiotic resistance. In addition, re-infection with <I>H. pylori</I> after antimicrobal therapy occurs frequently in countries where infection rates are high. Therefore, the only way to effectively prevent <I>H. pylori</I> (re)infection seems to be through long-term vaccination programs.

In the past 25 years since <I>H. pylori</I> has been first described and cultured, more than 20.000 publications have appeared on the subject. Understanding how this organism interacts with its host is of fundamental importance for preparation an intelligent strategy to prevent and cure <I>H. pylori</I> infections. To date, some promising approaches in vaccine development have been tested but still an effective vaccine against <I>H. pylori</I> remains to be demonstrated. Current knowledge of immunology, especially TLR activation and subsequent signaling, has enabled our team to design and test out some innovative ideas in vaccine development.
</DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2008.igem.org/Team:Slovenia/Background/The_problem">http://2008.igem.org/Team:Slovenia/Background/The_problem</A>&quot;</DIV></LEFT></LEFT></DIV></DIV><DIV id="footer-box"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:Slovenia/Background/The_problem" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:Slovenia/Background/The_problem" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:Slovenia/Background/The_problem&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:Slovenia/Background/The_problem&amp;oldid=104239" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2008.igem.org:Privacy_policy" title="2008.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2008.igem.org:General_disclaimer" title="2008.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></BODY></HTML>